Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors.
EP300
EWSR1
FOXO1
Gene fusion
Neuroepithelial tumor
PLAGL1
Supratentorial
Journal
Acta neuropathologica
ISSN: 1432-0533
Titre abrégé: Acta Neuropathol
Pays: Germany
ID NLM: 0412041
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
28
04
2021
accepted:
29
07
2021
revised:
27
07
2021
pubmed:
7
8
2021
medline:
23
2
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
Ependymomas encompass a heterogeneous group of central nervous system (CNS) neoplasms that occur along the entire neuroaxis. In recent years, extensive (epi-)genomic profiling efforts have identified several molecular groups of ependymoma that are characterized by distinct molecular alterations and/or patterns. Based on unsupervised visualization of a large cohort of genome-wide DNA methylation data, we identified a highly distinct group of pediatric-type tumors (n = 40) forming a cluster separate from all established CNS tumor types, of which a high proportion were histopathologically diagnosed as ependymoma. RNA sequencing revealed recurrent fusions involving the pleomorphic adenoma gene-like 1 (PLAGL1) gene in 19 of 20 of the samples analyzed, with the most common fusion being EWSR1:PLAGL1 (n = 13). Five tumors showed a PLAGL1:FOXO1 fusion and one a PLAGL1:EP300 fusion. High transcript levels of PLAGL1 were noted in these tumors, with concurrent overexpression of the imprinted genes H19 and IGF2, which are regulated by PLAGL1. Histopathological review of cases with sufficient material (n = 16) demonstrated a broad morphological spectrum of tumors with predominant ependymoma-like features. Immunohistochemically, tumors were GFAP positive and OLIG2- and SOX10 negative. In 3/16 of the cases, a dot-like positivity for EMA was detected. All tumors in our series were located in the supratentorial compartment. Median age of the patients at the time of diagnosis was 6.2 years. Median progression-free survival was 35 months (for 11 patients with data available). In summary, our findings suggest the existence of a novel group of supratentorial neuroepithelial tumors that are characterized by recurrent PLAGL1 fusions and enriched for pediatric patients.
Identifiants
pubmed: 34355256
doi: 10.1007/s00401-021-02356-6
pii: 10.1007/s00401-021-02356-6
pmc: PMC8500895
doi:
Substances chimiques
Cell Cycle Proteins
0
PLAGL1 protein, human
0
Transcription Factors
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
827-839Subventions
Organisme : Medical Research Council
ID : G0701018
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1100578
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N004272/1
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Cancer Lett. 2008 Oct 18;270(1):10-8
pubmed: 18457914
Surg Pathol Clin. 2019 Mar;12(1):165-190
pubmed: 30709442
Acta Neuropathol. 2012 May;123(5):727-38
pubmed: 22322993
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
J Appl Genet. 2017 Feb;58(1):71-78
pubmed: 27311313
Acta Neuropathol. 2018 Aug;136(2):211-226
pubmed: 29909548
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Cancer Discov. 2021 Sep;11(9):2216-2229
pubmed: 33741711
Nature. 2014 Feb 27;506(7489):451-5
pubmed: 24553141
Acta Neuropathol. 2018 Aug;136(2):227-237
pubmed: 30019219
Hum Pathol. 2019 Nov;93:65-73
pubmed: 31430493
Bioinformatics. 2014 May 15;30(10):1363-9
pubmed: 24478339
Dev Cell. 2006 Nov;11(5):711-22
pubmed: 17084362
J Neuropathol Exp Neurol. 2016 Apr;75(4):295-8
pubmed: 26945037
Genome Res. 2021 Mar;31(3):448-460
pubmed: 33441414
Brain Pathol. 2021 May;31(3):e12934
pubmed: 33378126
Cancer Res. 2009 Oct 15;69(20):7953-9
pubmed: 19808959
Genome Biol. 2014;15(12):550
pubmed: 25516281
Acta Neuropathol. 2021 Mar;141(3):455-466
pubmed: 33481105
Sci Rep. 2020 Jul 16;10(1):11837
pubmed: 32678267
Cancer Discov. 2021 Sep;11(9):2200-2215
pubmed: 33741710
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
J Cell Physiol. 2007 Jan;210(1):16-25
pubmed: 17063461
Dev Dyn. 2005 Jun;233(2):667-79
pubmed: 15844099
Acta Neuropathol. 2017 Nov;134(5):705-714
pubmed: 28733933
Mod Pathol. 2021 May;34(5):934-941
pubmed: 33318580
Neuro Oncol. 2018 Nov 12;20(12):1616-1624
pubmed: 30053291
Brain Pathol. 2019 Jan;29(1):53-62
pubmed: 29679497
Brain Pathol. 2021 May;31(3):e12943
pubmed: 33576087
J Neuropathol Exp Neurol. 2004 May;63(5):499-509
pubmed: 15198128
Brain Pathol. 2019 May;29(3):325-335
pubmed: 30325077
Neuro Oncol. 2017 Jul 1;19(7):986-996
pubmed: 28104717
Acta Neuropathol. 2019 Nov;138(5):827-835
pubmed: 31278449
Acta Neuropathol Commun. 2020 Nov 2;8(1):178
pubmed: 33138864
Neurooncol Adv. 2020 Nov 27;2(1):vdaa163
pubmed: 33392508
Acta Neuropathol. 2019 Dec;138(6):1075-1089
pubmed: 31414211
Cancer Cell. 2011 Aug 16;20(2):143-57
pubmed: 21840481
Cancer Discov. 2021 Sep;11(9):2230-2247
pubmed: 33879448
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Brain Pathol. 2021 Jan;31(1):70-83
pubmed: 32997853
Anticancer Res. 2016 Feb;36(2):617-24
pubmed: 26851016
Acta Neuropathol. 2016 Jun;131(6):903-10
pubmed: 26671409
J Neurooncol. 2011 Sep;104(2):423-38
pubmed: 21193945
PLoS Comput Biol. 2011 May;7(5):e1001138
pubmed: 21625565